TROP2 Antibody-Drug Conjugate: Unique Epitope Engagement Drives Differentiated Efficacy

Development of SDP0505: a first-in-class HER3\xa0\xd7\xa0c-Met bispecific ADC, demonstrates potent antitumor activity in EGFR TKI-resistant NSCLC, CRC, and beyond

Ivonescimab and other anti-programmed death-1/ligand 1 (PD-(L)1)/vascular endothelial growth factor (VEGF) bispecific antibodies: progress and prospects in cancer therapy

Preclinical characterization of IBD0333, a novel CD24\xd74-1BB bispecific antibody with tumor-dependent agonistic activity for cancer immunotherapy

A hyperimmune ovine antibody-based therapeutic candidate against Crimean-Congo haemorrhagic fever virus targeted to the Gn and Gc glycoproteins: high antibody levels with neutralization activity but lack of protective efficacy in a mouse model.

Application of a novel LC\u2013MS-based proteomic workflow for host cell protein monitoring and risk control in biotherapeutics

TROP2 Antibody-Drug Conjugate: Unique Epitope Engagement Drives Differentiated Efficacy

Development of SDP0505: a first-in-class HER3\xa0\xd7\xa0c-Met bispecific ADC, demonstrates potent antitumor activity in EGFR TKI-resistant NSCLC, CRC, and beyond

Ivonescimab and other anti-programmed death-1/ligand 1 (PD-(L)1)/vascular endothelial growth factor (VEGF) bispecific antibodies: progress and prospects in cancer therapy

Preclinical characterization of IBD0333, a novel CD24\xd74-1BB bispecific antibody with tumor-dependent agonistic activity for cancer immunotherapy

A hyperimmune ovine antibody-based therapeutic candidate against Crimean-Congo haemorrhagic fever virus targeted to the Gn and Gc glycoproteins: high antibody levels with neutralization activity but lack of protective efficacy in a mouse model.

Application of a novel LC\u2013MS-based proteomic workflow for host cell protein monitoring and risk control in biotherapeutics